GALECTIN THERAPEUTICS INC. Cash and Restricted Cash
GALECTIN THERAPEUTICS INC. (GALT) had Cash and Restricted Cash of $13.27 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-14
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $13.27M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $14.11M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $17.72M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $11.53M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $13.27M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $14.11M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $17.72M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $11.53M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $13.77M 10-Q · filed 2026-08-14 |
| 2025-03-31 | $7.43M 10-Q · filed 2026-05-15 |
| 2024-12-31 | $15.12M 10-Q · filed 2026-08-14 |
| 2024-09-30 | $27.06M 10-Q · filed 2025-11-14 |
| 2024-06-30 | $25.60M 10-Q · filed 2025-08-14 |
| 2024-03-31 | $23.55M 10-Q · filed 2025-05-15 |
| 2023-12-31 | $25.66M 10-K · filed 2026-03-31 |
| 2023-09-30 | $20.36M 10-Q · filed 2024-11-14 |
| 2023-06-30 | $17.97M 10-Q · filed 2024-08-13 |
| 2023-03-31 | $18.00M 10-Q · filed 2024-05-15 |
| 2022-12-31 | $18.59M 10-K · filed 2025-03-31 |
| 2022-09-30 | $15.83M 10-Q · filed 2023-11-13 |
| 2022-06-30 | $24.18M 10-Q · filed 2023-08-14 |
| 2022-03-31 | $31.61M 10-Q · filed 2023-05-15 |
| 2021-12-31 | $39.65M 10-K · filed 2024-03-29 |
| 2021-09-30 | $36.60M 10-Q · filed 2022-11-14 |
| 2021-06-30 | $31.60M 10-Q · filed 2022-08-15 |
| 2021-03-31 | $20.76M 10-Q · filed 2022-05-16 |
| 2020-12-31 | $27.14M 10-K · filed 2023-03-30 |
| 2020-09-30 | $32.56M 10-Q · filed 2021-11-15 |
| 2019-12-31 | $47.48M 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |